Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024)

Historic EBIT Margin for Fulcrum Therapeutics (FULC) over the last 5 years, with Q2 2024 value amounting to 65.61%.

  • Fulcrum Therapeutics' EBIT Margin rose 31669800.0% to 65.61% in Q2 2024 from the same period last year, while for Dec 2024 it was 27.37%, marking a year-over-year increase of 39178700.0%. This contributed to the annual value of 27.37% for FY2024, which is 39178700.0% up from last year.
  • As of Q2 2024, Fulcrum Therapeutics' EBIT Margin stood at 65.61%, which was up 31669800.0% from 3213.78% recorded in Q4 2023.
  • Fulcrum Therapeutics' 5-year EBIT Margin high stood at 65.61% for Q2 2024, and its period low was 9471.19% during Q1 2023.
  • Over the past 5 years, Fulcrum Therapeutics' median EBIT Margin value was 1033.77% (recorded in 2020), while the average stood at 2044.08%.
  • As far as peak fluctuations go, Fulcrum Therapeutics' EBIT Margin crashed by -84681800bps in 2023, and later skyrocketed by 31669800bps in 2024.
  • Fulcrum Therapeutics' EBIT Margin (Quarter) stood at 420.99% in 2020, then fell by -11bps to 465.78% in 2021, then tumbled by -777bps to 4083.65% in 2022, then rose by 21bps to 3213.78% in 2023, then soared by 102bps to 65.61% in 2024.
  • Its EBIT Margin was 65.61% in Q2 2024, compared to 3213.78% in Q4 2023 and 3615.28% in Q3 2023.